Shots:

• The company initiates the (ALVOEYE) confirmatory study of AVT06, a biosimilar to Eylea in ~444 patients with eye disorders that can lead to vision loss or blindness incl. wet AMD, macular edema & DR. The 1EPs is the change in BVCA from baseline to 8wk.
• The purpose of the study is to compare AVT06 & Eylea in terms of efficacy, safety & immunogenicity in adult patients with neovascular (wet) AMD
• AVT02 (biosimilar, adalimumab) has been approved and launched in Canada & the EU and is slated to do the same in the US on July 1, 2023. The company also reported the positive results for AVT04, a proposed biosimilar to Stelara from confirmatory clinical, safety, efficacy & PK study

Ref: Globenewswire | Image: Alvotech